Loading...
Aurobindo Pharma Ltd — Ciprofloxacin Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #5 for Ciprofloxacin · $11.4M export value · DGFT Verified
Aurobindo Pharma Ltd is the #5 Indian exporter of Ciprofloxacin with $11.4M in export value and 250 verified shipments. Aurobindo Pharma Ltd holds a 3.8% market share in Ciprofloxacin exports across 13 countries.
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $5.7M | 140 | 66.8% |
| MALTA | $1.0M | 114 | 12.0% |
| CANADA | $662.2K | 31 | 7.7% |
| UNITED KINGDOM | $304.8K | 28 | 3.6% |
| MEXICO | $218.5K | 13 | 2.6% |
| HONDURAS | $216.3K | 9 | 2.5% |
| FINLAND | $160.0K | 11 | 1.9% |
| SOUTH AFRICA | $77.0K | 3 | 0.9% |
| SWEDEN | $66.1K | 6 | 0.8% |
| PANAMA | $59.7K | 2 | 0.7% |
Aurobindo Pharma Ltd exports Ciprofloxacin to 15 countries. The largest destination is UNITED STATES accounting for 66.8% of Aurobindo Pharma Ltd's Ciprofloxacin shipments, followed by MALTA (12.0%) and CANADA (7.7%). These destinations reflect Aurobindo Pharma Ltd's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| AUROLOGISTICS LLC (AUROBINDO PHARMA | UNITED STATES | $1.5M | 39 |
| AUROLOGISTICS LLC | UNITED STATES | $1.2M | 30 |
| AUROLOGISTICS LLC(AUROBINDO PHARMA | UNITED STATES OF AMERICA | $894.4K | 23 |
| AUROLOGISTICS LLC, (AUROBINDO PHARM | UNITED STATES | $874.4K | 21 |
| AUROLOGISTICS LLC AUROBINDO PHARM | UNITED STATES | $701.2K | 18 |
| APL SWIFT SERVICES (MALTA) LTD., |
India exported $74.6M worth of Ciprofloxacin through 14,146 shipments from 1001 suppliers to 180 countries, serving 3,081 buyers globally. Aurobindo Pharma Ltd contributes $11.4M to this total, accounting for 3.8% of India's Ciprofloxacin exports. Aurobindo Pharma Ltd ships Ciprofloxacin to 15 countries through 43 buyers.
Aurobindo Pharma Ltd's average Ciprofloxacin shipment value is $45.4K per consignment, based on 250 shipments totaling $11.4M. The largest destination is UNITED STATES (66.8% of Aurobindo Pharma Ltd's Ciprofloxacin exports).
Aurobindo Pharma Ltd ranks #5 among 1001 Indian Ciprofloxacin exporters with a 3.8% market share. The top 3 exporters are SUN PHARMACEUTICAL INDUSTRIES LIMITED ($20.4M), AUROBINDO PHARMA LTD ($11.4M), SENTISS PHARMA PRIVATE LIMITED ($8.8M). Aurobindo Pharma Ltd processed 250 shipments to 13 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| CIPROFLOXACIN TABLETS 500MG (CIPROFLOXAC | $476.4K | 11 |
| CIPROFLOXACIN TABLETS 500MG (CIPROFLOXACIN TABLETS USP 500 MG) 100SNOS | $299.8K | 6 |
| CIPROFLOXACIN TABLETS 500MG(CIPROFLOXACI | $290.0K | 16 |
| CIPROFLOXACIN TABLETS 500MG(Ciprofloxaci | $284.6K | 11 |
| CIPROFLOXACIN TABLETS 500MG (Ciprofloxac | $204.3K | 9 |
| CIPROFLOXACIN TABLETS 500MG (Ciprofloxa | $196.0K | 6 |
| CIPROFLOXACIN TABLETS 500MG (CIPROFLOXACIN TABLETS USP 500 MG) 100'S | $173.4K | 4 |
| CIPROFLOXACIN TABLETS 500MG (CIPROFLOXACIN TABLETS USP 500 MG) 500'SNOS | $150.0K | 3 |
What Aurobindo Pharma Ltd must comply with to export Ciprofloxacin to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Approval Process
Exporters ranked immediately above and below #5 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $20.4M | 407 | 19 | $50.0K |
| 5 | AUROBINDO PHARMA LTD ★ | $11.4M | 250 | 13 | $45.4K |
| 6 | SENTISS PHARMA PRIVATE LIMITED | $8.8M | 177 | 7 | $50.0K |
| 9 | J B CHEMICALS AND PHARMACEUTICALS LIMITED | $5.3M |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 1,828 | 12.9% |
| SAHAR AIR | 1,481 | 10.5% |
| NHAVA SHEVA SEA (INNSA1) | 1,254 | 8.9% |
| DELHI AIR CARGO ACC (INDEL4) | 969 | 6.8% |
| JNPT/ NHAVA SHEVA SEA | 766 | 5.4% |
| DELHI AIR | 722 | 5.1% |
| JNPT | 595 | 4.2% |
| Bombay Air | 375 | 2.7% |
Latest developments and market context
Detailed market intelligence for Ciprofloxacin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Aurobindo Pharma Ltd's Ciprofloxacin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
| MALTA |
| $536.5K |
| 50 |
| AURO PHARMA INC | CANADA | $424.8K | 17 |
| APL SWIFT SERVICES MALTA LTD | MALTA | $381.6K | 21 |
| MILPHARM LIMITED | UNITED KINGDOM | $270.9K | 24 |
| AUROBINDO PHARMA USA.INC.,. | UNITED STATES | $200.0K | 4 |
Aurobindo Pharma Ltd supplies Ciprofloxacin to 43 buyers globally. The largest buyer is AUROLOGISTICS LLC (AUROBINDO PHARMA (UNITED STATES), followed by AUROLOGISTICS LLC (UNITED STATES) and AUROLOGISTICS LLC(AUROBINDO PHARMA (UNITED STATES OF AMERICA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
| CIPROFLOXACIN TABLETS 500MG (CIPROFLOXACIN TABLETS USP 500 MG)100'SNOS |
| $150.0K |
| 3 |
| CIPROFLOXACIN TABLETS 500MG (CIPROFLOXACIN TABLETS USP 500 MG)100'S | $150.0K | 3 |
Aurobindo Pharma Ltd exports 224 distinct Ciprofloxacin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is CIPROFLOXACIN TABLETS 500MG (CIPROFLOXAC with 11 shipments worth $476.4K.
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
| 196 |
| 7 |
| $27.1K |
Aurobindo Pharma Ltd ranks #5 among 1001 Indian Ciprofloxacin exporters. Average shipment value of $45.4K compared to the market average of $74.5K. The closest competitors by value are SUN PHARMACEUTICAL INDUSTRIES LIMITED and SENTISS PHARMA PRIVATE LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 180+ countries, 3,081+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Aurobindo Pharma Ltd.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Ciprofloxacin. For current shipment-level data, contact TransData Nexus.